NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Price Target & More

$28.09 +0.42 (+1.52 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$28.09
Today's Range$27.10 - $28.33
52-Week Range$13.50 - $44.00
Volume958,720 shs
Average Volume661,293 shs
Market Capitalization$741.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Debt-to-Equity Ratio1.55%
Current Ratio10.79%
Quick Ratio10.69%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$570,000.00
Price / Sales1,321.22
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book9.69

Profitability

EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net MarginsN/A
Return on Equity-95.30%
Return on Assets-59.49%

Miscellaneous

Employees147
Outstanding Shares26,810,000

How to Become a New Pot Stock Millionaire

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals (NASDAQ:ADMS) released its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by $0.09. The specialty pharmaceutical company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.84 million. The business's revenue was up 1435.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.68) earnings per share. View Adamas Pharmaceuticals' Earnings History.

What price target have analysts set for ADMS?

11 brokerages have issued 12 month price objectives for Adamas Pharmaceuticals' stock. Their forecasts range from $31.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' share price to reach $43.3750 in the next year. View Analyst Ratings for Adamas Pharmaceuticals.

What are Wall Street analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We believe Adamas is building a solid case for the importance of Gocovri within the Parkinson’s treatment paradigm, thereby increasing the company’s attractiveness as a takeout candidate longer-term. We reiterate our Buy rating and $49 PT." (4/20/2018)
  • 2. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (2/23/2018)

Who are some of Adamas Pharmaceuticals' key competitors?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went Ph.D., Co-Founder, Chairman & CEO (Age 54)
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
  • Dr. Rajiv Patni M.D., Chief Medical Officer (Age 49)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
  • Mr. Richard A. King, Chief Operating Officer (Age 53)

Has Adamas Pharmaceuticals been receiving favorable news coverage?

Press coverage about ADMS stock has trended somewhat positive on Saturday, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a daily sentiment score of 0.09 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 44.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include STATE STREET CORP (10.46%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $28.09.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $741.76 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]


MarketBeat Community Rating for Adamas Pharmaceuticals (ADMS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adamas Pharmaceuticals (NASDAQ:ADMS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Adamas Pharmaceuticals in the last 12 months. Their average twelve-month price target is $43.3750, suggesting that the stock has a possible upside of 54.41%. The high price target for ADMS is $55.00 and the low price target for ADMS is $31.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.3750$46.00$45.6667$39.50
Price Target Upside: 54.41% upside76.79% upside43.92% upside78.41% upside

Adamas Pharmaceuticals (NASDAQ:ADMS) Consensus Price Target History

Price Target History for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018MizuhoReiterated RatingBuy$49.00MediumView Rating Details
4/4/2018Leerink SwannInitiated CoverageOutperform -> Outperform$31.00HighView Rating Details
3/27/2018Bank of AmericaInitiated CoverageBuy$39.00HighView Rating Details
2/25/2018Needham & Company LLCSet Price TargetBuy$40.00LowView Rating Details
2/23/2018Noble FinancialReiterated RatingBuyLowView Rating Details
2/21/2018William BlairReiterated RatingOutperformLowView Rating Details
12/19/2017Piper JaffraySet Price TargetBuy$52.00LowView Rating Details
12/13/2017CowenSet Price TargetBuy$55.00HighView Rating Details
11/29/2017Northland SecuritiesInitiated CoverageOutperform -> OutperformLowView Rating Details
10/30/2017Evercore ISIInitiated CoverageOutperformN/AView Rating Details
8/25/2017JMP SecuritiesReiterated RatingMkt Outperform -> Outperform$29.00 -> $33.00HighView Rating Details
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings History and Estimates Chart

Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Estimates

2018 EPS Consensus Estimate: ($5.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.51)($1.41)($1.46)
Q2 20181($1.50)($1.50)($1.50)
Q3 20181($1.47)($1.47)($1.47)
Q4 20181($1.47)($1.47)($1.47)

Adamas Pharmaceuticals (NASDAQ ADMS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018Q4 2017($1.18)($1.27)$0.84 million$0.57 millionViewN/AView Earnings Details
11/2/2017Q3 2017($1.01)($1.04)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.93)$0.03 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.72)($0.72)$0.11 millionViewListenView Earnings Details
2/28/2017Q4($0.80)($0.68)$0.17 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.71)($0.78)$0.18 million$0.22 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)$0.18 millionViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)$0.10 million$0.52 millionViewN/AView Earnings Details
11/12/2015Q3($0.79)($0.81)$0.10 million$0.77 millionViewN/AView Earnings Details
8/11/2015Q215($0.67)($0.78)$0.10 million$0.40 millionViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)$0.10 million$0.23 millionViewN/AView Earnings Details
3/3/2015Q4 2014$0.64$0.50$30.18 million$30.30 millionViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)$0.18 million$0.22 millionViewN/AView Earnings Details
8/7/2014Q214$2.07$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.1760 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Adamas Pharmaceuticals (NASDAQ:ADMS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 77.33%
Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/21/2018Christopher B PrentissCAOSell567$25.98$14,730.6617,758View SEC Filing  
3/21/2018Gregory T WentCEOSell4,541$25.75$116,930.75182,610View SEC Filing  
3/21/2018Rajiv PatniInsiderSell1,252$25.94$32,476.8821,515View SEC Filing  
12/21/2017Jennifer J. RhodesInsiderSell440$32.30$14,212.00View SEC Filing  
6/21/2017Great Point Partners LlcMajor ShareholderSell380,000$17.08$6,490,400.00View SEC Filing  
6/21/2017Jennifer J. RhodesInsiderSell1,041$17.53$18,248.73View SEC Filing  
6/19/2017Great Point Partners LlcMajor ShareholderSell350,000$17.05$5,967,500.00View SEC Filing  
3/21/2017Gregory T WentCEOSell2,807$17.03$47,803.21166,526View SEC Filing  
3/21/2017Rajiv PatniInsiderSell733$17.04$12,490.3213,642View SEC Filing  
3/21/2017William J DawsonCFOSell716$17.02$12,186.3214,284View SEC Filing  
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.0021,006View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.0048,000View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.0054,000View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.0057,000View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Adamas Pharmaceuticals (NASDAQ ADMS) News Headlines

Source:
DateHeadline
Mizuho Reiterates "Buy" Rating for Adamas Pharmaceuticals (ADMS)Mizuho Reiterates "Buy" Rating for Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - April 20 at 7:46 AM
Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?
finance.yahoo.com - April 19 at 4:49 PM
Adamas Pharmaceuticals (ADMS) Expected to Announce Quarterly Sales of $1.68 MillionAdamas Pharmaceuticals (ADMS) Expected to Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - April 19 at 3:06 AM
Q1 2018 EPS Estimates for Adamas Pharmaceuticals Decreased by Analyst (ADMS)Q1 2018 EPS Estimates for Adamas Pharmaceuticals Decreased by Analyst (ADMS)
www.americanbankingnews.com - April 18 at 7:58 AM
JFs Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th ...JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th ...
seekingalpha.com - April 17 at 4:46 PM
 Brokerages Anticipate Adamas Pharmaceuticals (ADMS) Will Announce Earnings of -$1.38 Per Share Brokerages Anticipate Adamas Pharmaceuticals (ADMS) Will Announce Earnings of -$1.38 Per Share
www.americanbankingnews.com - April 17 at 1:19 PM
Adamas Pharmaceuticals (ADMS) PT Set at $45.00 by CowenAdamas Pharmaceuticals (ADMS) PT Set at $45.00 by Cowen
www.americanbankingnews.com - April 11 at 7:53 PM
Adamas Pharmaceuticals (ADMS) Upgraded to "Sell" by BidaskClubAdamas Pharmaceuticals (ADMS) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 9 at 10:19 PM
3 Things In Biotech, April 5: Pfizers Game Changer, Adamas Tackles MS, Aeglea Dives Into Small Cell3 Things In Biotech, April 5: Pfizer's Game Changer, Adamas Tackles MS, Aeglea Dives Into Small Cell
seekingalpha.com - April 6 at 9:29 AM
Adamas Pharmaceuticals (ADMS) to Post Q1 2018 Earnings of ($1.41) Per Share, Leerink Swann ForecastsAdamas Pharmaceuticals (ADMS) to Post Q1 2018 Earnings of ($1.41) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 6 at 6:48 AM
Adamas Pharma (ADMS) Reports 1st Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking ImpairmentAdamas Pharma (ADMS) Reports 1st Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
www.streetinsider.com - April 5 at 9:31 AM
Adamas Pharmaceuticals (ADMS) Given Average Rating of "Buy" by BrokeragesAdamas Pharmaceuticals (ADMS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 5:34 PM
Adamas Pharmaceuticals (ADMS) Now Covered by Leerink SwannAdamas Pharmaceuticals (ADMS) Now Covered by Leerink Swann
www.americanbankingnews.com - April 4 at 9:30 AM
Adamas Pharmaceuticals (ADMS) Upgraded at ValuEngineAdamas Pharmaceuticals (ADMS) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking ImpairmentAdamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
finance.yahoo.com - April 3 at 9:25 AM
$1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter$1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter
www.americanbankingnews.com - April 2 at 3:06 AM
Adamas Pharmaceuticals (ADMS) Price Target Raised to $48.00Adamas Pharmaceuticals (ADMS) Price Target Raised to $48.00
www.americanbankingnews.com - April 1 at 9:41 AM
Zacks: Brokerages Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Post Earnings of -$1.37 Per ShareZacks: Brokerages Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Post Earnings of -$1.37 Per Share
www.americanbankingnews.com - March 31 at 1:20 PM
Adamas Pharmaceuticals (ADMS) Upgraded at Zacks Investment ResearchAdamas Pharmaceuticals (ADMS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to SellAdamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 27 at 5:10 PM
Gocovri Stabilizes Adamas Stock, Secures Another Buy RatingGocovri Stabilizes Adamas Stock, Secures Another Buy Rating
finance.yahoo.com - March 27 at 4:47 PM
Adamas Pharmaceuticals (ADMS) Earns Buy Rating from Analysts at Bank of AmericaAdamas Pharmaceuticals (ADMS) Earns Buy Rating from Analysts at Bank of America
www.americanbankingnews.com - March 27 at 10:07 AM
Adamas: Valuation ReportAdamas: Valuation Report
seekingalpha.com - March 27 at 9:10 AM
Christopher B. Prentiss Sells 567 Shares of Adamas Pharmaceuticals Inc (ADMS) StockChristopher B. Prentiss Sells 567 Shares of Adamas Pharmaceuticals Inc (ADMS) Stock
www.americanbankingnews.com - March 22 at 8:13 PM
Adamas Pharmaceuticals Inc (ADMS) Insider Sells $32,476.88 in StockAdamas Pharmaceuticals Inc (ADMS) Insider Sells $32,476.88 in Stock
www.americanbankingnews.com - March 22 at 8:13 PM
Gregory T. Went Sells 4,541 Shares of Adamas Pharmaceuticals Inc (ADMS) StockGregory T. Went Sells 4,541 Shares of Adamas Pharmaceuticals Inc (ADMS) Stock
www.americanbankingnews.com - March 22 at 7:32 PM
Adamas Pharmaceuticals (ADMS) versus CymaBay Therapeutics (CBAY) Financial AnalysisAdamas Pharmaceuticals (ADMS) versus CymaBay Therapeutics (CBAY) Financial Analysis
www.americanbankingnews.com - March 20 at 7:10 PM
Edited Transcript of ADMS earnings conference call or presentation 22-Feb-18 9:30pm GMTEdited Transcript of ADMS earnings conference call or presentation 22-Feb-18 9:30pm GMT
finance.yahoo.com - March 20 at 4:49 PM
Adamas Pharma (ADMS) Announces Publication of Data Supporting Benefits of GOCOVRI in PD Patients with ... - StreetInsider.comAdamas Pharma (ADMS) Announces Publication of Data Supporting Benefits of GOCOVRI in PD Patients with ... - StreetInsider.com
www.streetinsider.com - March 16 at 10:03 AM
Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with DyskinesiaAdamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
finance.yahoo.com - March 15 at 10:18 AM
Adamas Pharmaceuticals Inc (ADMS) Expected to Post Earnings of -$1.32 Per ShareAdamas Pharmaceuticals Inc (ADMS) Expected to Post Earnings of -$1.32 Per Share
www.americanbankingnews.com - March 14 at 12:01 PM
Adamas stock rises 5% on strong launch of Parkinsons drug - MarketWatchAdamas stock rises 5% on strong launch of Parkinson's drug - MarketWatch
www.marketwatch.com - March 13 at 5:00 PM
BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct PrescribersBRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
www.reuters.com - March 13 at 10:50 AM
Pre-Open Movers 03/12: (OCLR) (ADMS) (MU) Higher; (ANTH) (SVRA) (ESPR) Lower (more...)Pre-Open Movers 03/12: (OCLR) (ADMS) (MU) Higher; (ANTH) (SVRA) (ESPR) Lower (more...)
www.streetinsider.com - March 12 at 4:44 PM
What Should Investors Know About Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Future?What Should Investors Know About Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Future?
finance.yahoo.com - March 12 at 4:44 PM
Adamas stock rises 5% on strong launch of Parkinsons drugAdamas stock rises 5% on strong launch of Parkinson's drug
finance.yahoo.com - March 12 at 4:44 PM
Adamas Pharmaceuticals Inc (ADMS) Given Consensus Rating of "Buy" by AnalystsAdamas Pharmaceuticals Inc (ADMS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 10 at 6:12 PM
Adamas Pharmaceuticals (ADMS) Upgraded to Hold by BidaskClubAdamas Pharmaceuticals (ADMS) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - March 10 at 9:45 AM
Tamarack Advisers LP Takes Position in Adamas Pharmaceuticals Inc (ADMS)Tamarack Advisers LP Takes Position in Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - March 6 at 10:30 AM
Mosaic Family Wealth LLC Sells 26,000 Shares of Adamas Pharmaceuticals Inc (ADMS)Mosaic Family Wealth LLC Sells 26,000 Shares of Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - March 6 at 8:48 AM
Adamas Pharmaceuticals (ADMS) Cut to Sell at BidaskClubAdamas Pharmaceuticals (ADMS) Cut to Sell at BidaskClub
www.americanbankingnews.com - March 4 at 12:16 AM
EAM Investors LLC Buys 4,792 Shares of Adamas Pharmaceuticals Inc (ADMS)EAM Investors LLC Buys 4,792 Shares of Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - February 28 at 1:56 PM
American Century Companies Inc. Acquires New Stake in Adamas Pharmaceuticals Inc (ADMS)American Century Companies Inc. Acquires New Stake in Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - February 27 at 4:06 AM
Adamas Pharmaceuticals (ADMS) PT Set at $40.00 by Needham & Company LLCAdamas Pharmaceuticals (ADMS) PT Set at $40.00 by Needham & Company LLC
www.americanbankingnews.com - February 26 at 11:26 AM
Adamas Pharmaceuticals (ADMS) Rating Reiterated by Noble FinancialAdamas Pharmaceuticals (ADMS) Rating Reiterated by Noble Financial
www.americanbankingnews.com - February 24 at 11:58 AM
Adamas Pharmaceuticals (ADMS) Downgraded by Zacks Investment ResearchAdamas Pharmaceuticals (ADMS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 23 at 5:51 PM
Here's Why Adamas Pharmaceuticals Dropped TodayHere's Why Adamas Pharmaceuticals Dropped Today
finance.yahoo.com - February 23 at 4:43 PM
Research Analysts Set Expectations for Adamas Pharmaceuticals Incs FY2018 Earnings (ADMS)Research Analysts Set Expectations for Adamas Pharmaceuticals Inc's FY2018 Earnings (ADMS)
www.americanbankingnews.com - February 23 at 1:22 PM
Adamas Pharmaceuticals (ADMS) Issues  Earnings ResultsAdamas Pharmaceuticals (ADMS) Issues Earnings Results
www.americanbankingnews.com - February 23 at 12:01 PM
Adamas reports 4Q lossAdamas reports 4Q loss
finance.yahoo.com - February 23 at 9:27 AM

SEC Filings

Adamas Pharmaceuticals (NASDAQ:ADMS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Adamas Pharmaceuticals (NASDAQ:ADMS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Adamas Pharmaceuticals (NASDAQ ADMS) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.